Ketamine therapy has quickly become one of the most promising treatments for depression, PTSD, and other challenging mental health conditions. Over the past decade, both clinical experience and scientific research have shed light on how ketamine works and how it can be used safely and effectively in clinical settings.
Recently, several important developments have provided new insights to the field. Researchers have published new brain imaging studies investigating ketamine’s effects on neuroplasticity, another study has looked into whether the psychedelic experience itself is necessary for healing, and regulators in Texas have proposed new rules that could change how ketamine clinics operate.
These developments help clarify both the science and the changing landscape of ketamine therapy. Understanding them can help patients make more informed treatment choices and better grasp the mechanisms behind ketamine’s therapeutic effects.
Brain Imaging Research Offers New Clues About How Ketamine Works
For many years, scientists have known that ketamine can produce rapid antidepressant effects. Unlike traditional antidepressants—which often take weeks to begin working—ketamine can improve depressive symptoms within hours or days. However, exactly how ketamine achieves these effects has remained an area of active research.
A recent brain imaging study has provided new evidence pointing toward the role of AMPA receptors, which are critical components of how brain cells communicate with one another. AMPA receptors are part of the brain’s glutamate signaling system. Glutamate is the brain’s primary excitatory neurotransmitter and plays a key role in learning, memory, and neuroplasticity—the brain’s ability to reorganize itself by forming new neural connections.
In the study, researchers used advanced imaging techniques to measure the baseline density of AMPA receptors in different regions of the brain among individuals suffering from depression. They found that people with more severe depression tended to show abnormal patterns of receptor activity.
After undergoing a series of ketamine infusions, researchers observed significant changes in these patterns. Importantly, the degree of improvement in depressive symptoms appeared to correlate with baseline AMPA receptor activity in specific brain regions.
In simple terms, individuals whose brains showed certain receptor patterns before treatment were more likely to experience significant improvement following ketamine therapy.
These findings support a growing body of research suggesting that ketamine works in part by enhancing glutamate signaling and activating AMPA receptors. This cascade of activity is believed to stimulate the release of brain-derived neurotrophic factor (BDNF), a molecule that promotes the growth and strengthening of synaptic connections between neurons.
The result is an increase in neuroplasticity—the brain’s ability to rewire itself and recover from the rigid patterns often seen in depression. For patients struggling with mood disorders, this is an important concept. Depression is not simply a chemical imbalance but often involves entrenched patterns of neural communication that reinforce negative thinking, emotional numbness, and reduced motivation.
By temporarily increasing neuroplasticity, ketamine may help the brain regain flexibility and open a window for new patterns of thought, emotion, and behavior to emerge. This is one reason why psychotherapy, lifestyle changes, and supportive practices during and after ketamine treatment can be so powerful. When the brain becomes more plastic, it may be more receptive to therapeutic interventions that reinforce healthier mental patterns.
This blog is proudly sponsored by Newy, the first physician-formulated mental health supplement created to boost neuroplasticity, support brain health, and complement ketamine therapy.
Is the Psychedelic Experience Necessary for Ketamine to Work?
Ketamine therapy is often associated with psychedelic or dissociative experiences. Some patients describe sensations such as altered perception, feelings of floating, or a temporary sense of detachment from their body or surroundings. These experiences can sometimes be profound and may lead to meaningful personal insights or emotional breakthroughs, which has led many people to assume that the psychedelic experience itself is the primary driver of ketamine’s therapeutic effects.
However, new research suggests that this may not be the case. A recent study examining intravenous ketamine for alcohol use disorder investigated whether the intensity of the subjective psychedelic experience predicted treatment success. Participants reported varying levels of dissociation and perceptual changes during treatment—some individuals had intense experiences, while others reported only mild alterations in perception. Researchers then analyzed whether these subjective experiences predicted clinical outcomes, specifically reductions in alcohol consumption and the number of days participants remained sober after treatment.
Surprisingly, the study found no correlation between the intensity of the psychedelic experience and treatment success. Patients who reported powerful dissociative experiences were no more likely to remain sober than those who experienced milder effects. These findings suggest that the therapeutic benefits of ketamine may arise primarily from its biological effects on the brain rather than the psychological experience during treatment.
This observation aligns closely with what many clinicians see in practice. In ketamine clinics across the country, patients often report widely varying subjective experiences—some have vivid internal experiences during infusions, while others feel relatively calm or lightly sedated—yet both groups can experience meaningful improvements in mood, anxiety, or other symptoms in the days following treatment.
One of the clearest examples of this principle can be seen with intranasal esketamine (Spravato). Many patients receiving Spravato experience little to no psychedelic effects, yet clinical trials and real-world data consistently demonstrate robust antidepressant benefits. For patients considering ketamine therapy, this can be reassuring. The goal of treatment is not necessarily to achieve a dramatic psychedelic experience; instead, clinicians are primarily focused on the therapeutic changes that occur in the brain in the days and weeks after treatment. While the subjective experience can sometimes provide valuable insights, it is not required for the therapy to work.
Texas Proposes New Regulations for Ketamine Clinics
As ketamine therapy continues to grow in popularity, regulators across the United States are beginning to consider how best to oversee its use. Recently, the Texas Medical Board proposed new regulations that would significantly tighten oversight of ketamine clinics operating within the state. One of the most notable provisions would require a physician to be physically present on-site during every ketamine treatment, effectively prohibiting remote physician supervision—a model used by some clinics in which nurses administer treatment while a physician oversees multiple locations.
The proposed rules also introduce several additional requirements, including:
-
Stricter patient monitoring protocols during ketamine treatments
-
Mandatory physician training in mental health care or ketamine therapy
-
Clear documentation of qualifying psychiatric diagnoses—such as treatment-resistant depression, PTSD, or suicidal ideation—before treatment can be provided
-
Additional standards for clinic safety and operational oversight to ensure appropriate administration of ketamine therapy
Supporters of these regulations argue that stronger oversight is necessary to protect patient safety and ensure ketamine is administered responsibly. Ketamine is a powerful medication that can produce significant psychological and physiological effects, making proper screening, monitoring, and clinical supervision essential components of safe treatment.
Critics of the proposal, however, worry that overly strict rules could unintentionally limit access to care. In many parts of the country, ketamine clinics already fill an important gap in mental health services for individuals who have not responded to traditional treatments. Requiring a physician to be physically present during every treatment may make it more difficult for clinics—particularly those serving rural or underserved areas—to operate efficiently. As a result, the debate highlights a broader challenge that often accompanies emerging medical treatments: finding the right balance between ensuring patient safety and maintaining access to potentially life-changing care.
A Higher Standard of Care
Although California does not currently require a physician to be physically present during ketamine treatments, many clinics voluntarily maintain this level of oversight. At Innerbloom Ketamine Therapy, physician presence during treatment has always been a core part of our model of care. Every patient undergoing ketamine therapy at Innerbloom is treated in a closely monitored medical setting with a physician on-site throughout the entire session, allowing for real-time monitoring of vital signs, rapid response to any concerns, and the ability to adjust treatment parameters when needed.
Beyond safety, this approach reflects a broader philosophy about ketamine therapy. Ketamine is not simply a medication—it is part of a comprehensive therapeutic process that includes careful patient screening, thoughtful dosing, integration support, and collaboration with mental health professionals. Providing this level of care requires hands-on involvement from clinicians who are deeply familiar with the treatment. As ketamine therapy continues to evolve, both scientific research and regulatory frameworks will likely continue to shape how clinics operate.
The Future of Ketamine Therapy
The recent studies on AMPA receptors and the role of the psychedelic experience highlight how rapidly the scientific understanding of ketamine is evolving. Each new study helps clarify the mechanisms behind ketamine’s antidepressant effects and how treatment can be optimized for patients.
At the same time, regulatory discussions—such as the proposed rules in Texas—reflect the growing recognition that ketamine therapy is becoming an important part of modern mental health care. As with any emerging treatment, finding the right balance between safety, access, and clinical innovation will be essential.
For patients struggling with treatment-resistant depression, PTSD, or other severe mood disorders, ketamine therapy continues to offer a powerful and often life-changing option. With ongoing research, thoughtful clinical practice, and responsible oversight, the field will likely continue to expand, bringing new hope to individuals who have not found relief through conventional treatments.
About the Author
Dr. Rivas is a ketamine specialist and board-certified acute care and trauma surgeon with over 12 years of experience in ketamine administration. Before founding Innerbloom Ketamine Therapy in 2022, Dr. Rivas served on the frontlines of emergency and trauma medicine in Santa Maria, CA, and Austin, TX. Dr. Rivas applies his extensive medical expertise to provide safe, evidence-based ketamine treatments for mood disorders, including depression, anxiety, PTSD, and chronic pain. His passion lies in helping patients find relief and rediscover hope through personalized, compassionate care.
Newy: Bridging the Gap Between Ketamine Treatment and Everyday Wellness
A supplement formulated by Dr. Rivas for enhanced brain and mood support. The formula pairs especially well with ketamine therapy by helping extend and enhance the neuroplasticity effects. That said, the ingredients are equally effective on their own, so it’s a supportive option whether or not someone is undergoing ketamine treatment. Learn more about how Newy supports cognitive function detoxification and cellular repair.
References
Nakajima, W., Hatano, M., Ohtani, Y. et al. The dynamics of AMPA receptors underlies the efficacy of ketamine in treatment resistant patients with depression. Mol Psychiatry (2026). doi.org/10.1038/s41380-026-03510-w
King’s College London. “Ketamine High Not Related to Treatment Success for People with Alcohol Problems, Study Finds.” King’s College London, 17 Feb. 2026, https://www.kcl.ac.uk/news/ketamine-high-not-related-to-treatment-success-for-people-with-alcohol-problems-study-finds
Kim, Phil. “Texas Register January 2, 2026 Volume: 51 Number: 1.” Texas Health Law, 5 Jan. 2026. texhealthlaw.org/texas-register-january-2-2026-volume-51-number-1/.
Medical Disclaimer
All content on this website, including but not limited to this article, blog posts, testimonials, and FAQs, is not medical advice and should not be considered as such. This website cannot diagnose or treat any medical condition. Only a licensed medical professional who is familiar with you and your medical history can provide medical advice, diagnosis, or treatment.
The information provided here is for educational and informational purposes only. It is not intended to replace a consultation with a qualified healthcare provider. If you are experiencing symptoms of depression or any mental health condition, please consult with a licensed mental health professional or your primary care physician.
If you are in crisis or experiencing suicidal thoughts, please call the 988 Suicide and Crisis Lifeline (call or text 988) or go to your nearest emergency room immediately.
Innerbloom Ketamine Therapy cannot be held responsible or liable for any actions taken by those who access our website or rely on its content. Please refer to our Terms & Conditions for more information.
Ready to find out what life feels like without the gray filter? Contact Innerbloom Ketamine Therapy at (805) 592-5085 or visit us at 100 Casa Street, Suite D3, San Luis Obispo, CA 93405. We offer complimentary consultations to discuss your treatment options in a conversation that’s as unhurried as your healing deserves to be.